RESUMO
Although current data shows that chromium supplementation in type 2 Diabetic patients can improve control blood sugar and lipids there are controversial results about its relevance to improving blood sugar and lipids in diabetes. This study investigates the effect of chromium picolinate supplement on blood sugar and lipids control in patients with type 2 diabetes. This randomized, double-blind,placebo-controlled study was carried out at the Diabetes Clinic of the Loghman Hospital in collaboration with Taban Diabetes Clinic. In this clinical study of 60 patients with type 2 Diabetes, participants were randomized into the doubleblind treatment and control groups for 3 months of treatment with 200 g of chromium picolinate or placebo respectively. Blood sugar and lipids profile were assessed at the beginning and end of the study. Based on the result of this study it has been found that 200 micrograms of chromium consumed over three months could decrease of TG levels dramatically, compared to placebos. TG changes were significantly different between the two groups, [P=0.048], without any change in other lipid profiles of the two groups. Findings showed that chromium picolinate treatment for 90 days produced significant improvements in glycemic control compared to placebo, based on significant reductions in both FPG and HbA1c levels in patients with type 2 diabetes mellitus, with significant changes between the two groups [P<0.001]. Results of this study recommend that chromium picolinate prescribed to type 2 diabetes patients could decrease TG, HbA1c and FPG levels
RESUMO
Rheumatoid arthritis [RA] is the most common inflammatory arthritis affecting 0.5 to 1% of the general population worldwide. The cause of RA remains unknown. In active RA, bone turnover markers change in serum and urine before the appearance of erosions in radiography. In this study, we compared RA activity index with bone turnover marker levels in serum of RA patients. In this cross-sectional study, RA patients referring to the Rheumatology Clinic of Loghman Hospital were studied. One hundred fourteen established RA patients were included. Bone turnover markers were measured in 75 patients. DAS28 and cumulative dose of steroid were calculated in all patients. RF, Anti-CCP, ESR, CRP, bone turnover markers consisting of osteocalcin, P1NP, betaCTX and ALP were measured for all the patients. Cases were divided based on whether steroid and DMARD were used or not. Comparison of DAS28 and bone turnover markers was done with Chi square Pearson test. Also, the relation between bone turnover markers and consumption of DMARDs, steroid and bisphosphonate was evaluated. SPSS V. 16 was also used for data analysis. There was significant correlation between DAS28 and serum osteocalcin [p<0.05], but no correlation was found with other markers. There was significant correlation between bisphosphonate consumption and decreased serum osteocalcin [p=0.05] and borderline correlation with decreased P1NP [p=0.06]. Significant correlations was found between "erosion and decreased level of osteocalcin" and "erosion and DAS28".In active RA patients, decreased bone formation markers especially osteocalcin are suggestive of severe and erosive disease for which early aggressive treatment is recommended. These markers can be applied for differentiating osteoporosis from RA in these patients. Thus increased level of bone formation markers is seen in idiopathic osteoporosis and decreased level in active RA